Roux-en-Y gastric bypass and sleeve gastrectomy: Mechanisms of diabetes remission and role of gut hormones

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4391-4399

  Nannipieri, Monica ^a   Baldi, S ^a   Mari, A ^b   Colligiani, D ^a   Guarino, D ^a   Camastra, S ^a   Barsotti, E ^a   Berta, R ^c   Moriconi, D ^a   Bellini, R ^a   Anselmino, M ^c   Ferrannini, E ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; PANCREAS POLYPEPTIDE; PEPTIDE YY;

ARTICLE; BOUGIE; CLINICAL ARTICLE; ENDOCRINE FUNCTION; FEMALE; GASTROINTESTINAL STAPLER; GLUCOSE SENSITIVITY; HORMONE RESPONSE; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REMISSION; ROUX EN Y GASTRIC BYPASS; SLEEVE GASTRECTOMY; STOMACH BYPASS; TREATMENT OUTCOME;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRECTOMY; GASTRIC BYPASS; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLYCEMIC INDEX; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; MALE; MIDDLE AGED; OBESITY, MORBID; PANCREATIC POLYPEPTIDE; PEPTIDE YY; REMISSION INDUCTION;

EID: 84887455968     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2538     Document Type: Article

References (38)

1. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin- dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19: 477-490.
2. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24: 89-94.
3. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-256.e5.
4. Vetter ML, Cardillo S, RickelsMR,Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009;150: 94-103.
5. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367: 695-704.
6. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366: 1567-1576.
7. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150: 2518-2525.
8. Hickey MS, Pories WJ, MacDonald KG, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg. 1998;227:637-643; discussion 643-644.
9. Roslin MS, Dudiy Y, Weiskopf J, Damani T, Shah P. Comparison between RYGB, DS, and VSG effect on glucose homeostasis. Obes Surg. 2012;22: 1281-1286.
10. Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18: 1077-1082.
11. Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011;301:R15-R27.
12. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011; 7: 683-690.
13. Romero F, Nicolau J, Flores L, et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012;26: 2231-2239.
14. Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250: 234-241.
15. Chen CY, Fujimiya M, Laviano A, Chang FY, Lin HC, Lee SD. Modulation of ingestive behavior and gastrointestinal motility by ghrelin in diabetic animals and humans. J Chin Med Assoc. 2010; 73: 225-229.
16. YadaTDezaki K, Sone H, et al. Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential. Curr Diabetes Rev. 2008;4: 18-23.
17. American Diabetes Association. Tests of glycemia in diabetes (position statement). Diabetes Care. 2002;25(suppl 1):S97-S99.
18. Nannipieri M, Mari A, Anselmino M, et al. The role of β-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011;96:E1372- E1379.
19. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects.AmJ Physiol Endocrinol Metab. 2002;283:E1159-E1166.
20. Maki KC, Rains TM, Dicklin MR, Bell M. Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose. Diabetes Technol Ther. 2010;12: 895-900.
21. De Fronzo R, Matsuda M. Reduced time points to calculate the composite index. Diabetes Care. 2010;33:e93.
22. VanCauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41: 368-377.
23. Braghetto I, Davanzo C, Korn O, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg. 2009;19: 1515-1521.
24. Dirksen C, Damgaard M, Bojsem- Moller KN, et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass Neurogastroenterol Motil. 2013;25:346-e255.
25. Ramón JM, Salvans S, Crous X, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg. 2012;16:1116- 1122.
26. Bose M, Teixeira J, Olivan B, et al. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010;2: 47-55.
27. Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21: 896-901.
28. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247: 401-407.
29. Pournaras DJ, Osborne A, Hawkins SC, et al. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg. 2010;20: 56-60.
30. Camastra S, Muscelli E, Gastaldelli A, et al. 2013 Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients [published online ahead of print July 8, 2013]. Diabetes. doi:10.2337/db13-0321.
31. Boey D, Heilbronn L, Sainsbury A, et al. Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides. 2006;40: 317-324.
32. Keidar A, Hershkop KJ, Marko L, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: a randomised trial. Diabetologia. 2013;56: 1914-1918.
33. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36: 2175-2182.
34. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56: 965-972.
35. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29: 46-54.
36. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes. 2001;50: 609-613.
37. Holst JJ,KnopFK, Vilsbøll T, Krarup T,MadsbadS. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34:S251-S257.
38. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96: 737-745.